High Dose-Intense Chemotherapy Alone or in Combination with Interleukin-2 for Small Cell Lung Cancer: A Pilot Study

References

• Seifter EJ, Ihde DC. Therapy of small cell lung cancer: A perspective on two decades of clinical research. Semin Oncol 1988; 15: 278–299
   PubMed Web of Science ®Google Scholar
• Johnson BE, Grayson J, Makuch RW. Ten-year survival of patients with SCLC treated with a combination chemotherapy with or without irradiation. J Clin Oncol 1990; 8: 396–401
   PubMed Web of Science ®Google Scholar
• Carney DN, De Leij L. Lung cancer biology. Semin Oncol 1988; 15: 199–214
   PubMed Web of Science ®Google Scholar
• Kristjansen P EG, Hansen HH. Management of small cell lung cancer: A summary of the Third International Association for the study of lung cancer workshop on small cell lung cancer. J Nat Cancer Inst 1990; 82(4)263–266
   PubMed Web of Science ®Google Scholar
• Taylor CW, Crowley J, Williamson SK. Treatment of small cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: A Southwest Oncology Group pilot study. J Clin Oncol 1990; 8(11)1811–1817
   PubMed Web of Science ®Google Scholar
• Wampler GL, Ahlgren JD, Schulof RS. A pilot study of intensive weekly chemothreapy for extensive disease small-cell lung carcinoma. Cancer Invest 1992; 10(2)97–102
   PubMed Web of Science ®Google Scholar
• Murray N, Shah A, Osoba D. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 1991; 9: 1632–1638
   PubMed Web of Science ®Google Scholar
• Miles DW, Earl HM, Souhami RL. Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer. J Clin Oncol 1991; 9: 280–285
   PubMed Web of Science ®Google Scholar
• Alba E, Breton JJ, Alonso L, Paredes G, Belon J, Ballesteros P. Alternating chemotherapy for small-cell lung cancer. A twelve week schedule of six drugs. Ann Oncol 1992; 3: 31–35
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Sertoli MR, Corcione A. Accelerated chemotherapy with or without GM-CSF for small cell lung cancer: A nonrandomised pilot study. Eur J Cancer 1990; 26(9)937–941
   PubMed Web of Science ®Google Scholar
• Kudoh S, Fukuoka M, Negoro S. Weekly dose-intense chemotherapy in patients with small-cell lung cancer: A pilot study. Am J Clin Oncol (CCT) 1992; 15(1)29–34
   PubMed Web of Science ®Google Scholar
• Evans WK, Murray N, Feld R. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. An Intern Med 1987; 107: 451–458
   PubMed Web of Science ®Google Scholar
• Goldman AJ, Goldie JH. Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin Oncol 1987; 14(4)29–33, (Suppl 4)
   Web of Science ®Google Scholar
• Lotze MT, Matory YL, Ettinghausen SE. In vivo administration of purified human interleukin 2. II. Half-life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1985; 135(4)2865–2875
   PubMed Web of Science ®Google Scholar
• Tritarelli E, Rocca E, Testa U. Adoptive immunotherapy with high-dose interleukin-2: Kinetics of circulating progenitors correlate with interleukin-6, granulocyte colony-stimulating factor level. Blood 1991; 77(4)741–749
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 315: 889–897
   Google Scholar
• Gambacorta-Passerini C, Radrizzani M, Erba E. Lysis by activated lymphocytes of melanoma and small cell lung cancer cells surviving in vitro treatment with mafosfamide. Cancer Res 1987; 47: 2547–2552
   PubMed Web of Science ®Google Scholar
• Allavena P, Grandi M, D'Incalci M. Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin-2 activated killer cells and by activated monocytes. Int J Cancer 1987; 40: 104–107
   PubMed Web of Science ®Google Scholar
• Allavena P, Perovano P, Bonazzi C, Colombo N, Mantovani A, D'Incalci M. In vitro and in vivo effects of cisplatin on the generation of lymphokine-activated killer cells. J Natl Cancer Inst 1990; 82: 139–142
   PubMed Web of Science ®Google Scholar
• Schaafsma MR, Fibbe WE, Van der Harst D. Increased numbers of circulating hematopoietic progenitors cells after treatment with high-dose interleukin 2 in cancer patients. Br J Haematol 1990; 76: 180–185
   PubMed Web of Science ®Google Scholar
• Gambacorta-Passerini C, Hank JA, Borchert A, Moore K, Malkovska V, Sondel P. In vivo effects of multiple cycles of recombinant interleukin 2 on peripheral granulocyte-macrophage hematopoietic progenitors circulating in the blood of cancer patients. Tumori 1991; 77: 420–422
   PubMed Web of Science ®Google Scholar
• Mitchell MS. Combining chemotherapy with biological response modifiers in treatment of cancer. J Natl Cancer Inst 1988; 80(18)1445–1450
   PubMed Web of Science ®Google Scholar
• Parkinson DR. Interleukin-2 in cancer therapy. Semin Oncol 1988; 15: 10–26, (Suppl 6)
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Demchak P, Atkins M, Sell K, Givant E, Lipton A. Phase II study of interleukin 2 and interferon alpha-2-a outpatient therapy for metastatic renal cancer. Proc Am Soc Clin Oncol 1991; 10: A565
   Google Scholar
• Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. Important Advances in Oncology, VT DeVita, S Hellman, SE Rosenberg. Lippincott, Philadelphia 1988; 121–141
   Google Scholar
• Osterlind K, Hansen HH. Ways to a better treatment of small cell lung cancer: A commentary. Ann Oncol 1992; 3: 9–10
   PubMed Web of Science ®Google Scholar
• Goldie JH, Coldman AJ, Gudanskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982; 66: 439–449
   PubMedGoogle Scholar
• Roth BJ, Johnson DH, Einhorn LH. A randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 282–291
   PubMed Web of Science ®Google Scholar
• Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Murray N. The importance of dose-intensity in lung cancer chemotherapy. Semin Oncol 1987; 14(4)20–28, (suppl 4)
   PubMed Web of Science ®Google Scholar
• Miles DW, Souhami RL, Spiro SG. A randomized trial comparing “standard” 3 weekly with weekly chemotherapy in patients with small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1992; 11: 289
   Google Scholar
• Flaherty LE, Redman BG, Chabot CG. A phase I-II study of dacarbazine in combination with outpatient interleukin 2 in metastatic malignant melanoma. Cancer 1990; 65(11)2471–2477
   PubMed Web of Science ®Google Scholar
• Redman BG, Flaherty L, Chou TH, Nakeff A, Pillote K, Kaplan J. Sequential dacarbazine/cisplatin and interleukin 2 in metastatic melanoma: Immunologic effects of therapy. J Immunother 1991; 10(2)147–151
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Inzani V, Sadullah S. A phase II trial of recombinant interleukin 2 and 5-FU chemotherapy, in patients with metastatic colorectal carcinoma. Cancer Treat Rep 1989; 16: 163–167, (Suppl A)
   Google Scholar
• Paciucci PA, Bekesi JG, Ryder JS, Odchimar R, Chahinian PA, Holland JF. Immunotherapy with IL2 by constant infusion and weekly doxorubicin. Am J Clin Oncol 1991; 14(4)341–348
   PubMed Web of Science ®Google Scholar
• Valone FH, Gandara DR, Deisseroth AB. Interleukin 2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head and neck carcinomas. J Immunother 1991; 10(3)207–213
   PubMed Web of Science ®Google Scholar
• Clamon G, Ozer H, Herndon J, Perry M, Scalzo A, Green MR. Activity of interleukin 2 in patients with extensive small cell lung cancer. Proc Am Soc Clin Oncol 1992; 11: 312
   Google Scholar
• Spiro SG, Souhami RL, Geddes DM. Duration of chemotherapy in small cell lung cancer: A cancer research campaign trial. Br J Cancer 1989; 59: 578–583
   PubMed Web of Science ®Google Scholar